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 To my family 
 ABSTRACT 
   Chemotherapeutic agents have become widely applied for treatment of various types 
of malignancies. Drug resistance unfortunately remains as a major obstacle for the 
effectiveness of chemotherapy. Cancer drug resistance includes two broad categories: 
intrinsic and acquired. In this thesis I have examined the problem of acquired drug 
resistance and have aimed to develop novel approaches to overcome acquired 
resistance. 
    Clofarabine is a second-generation nucleoside analogue which has been employed 
primarily for the treatment of hematological malignancies. In paper I, we found that 
clofarabine inhibited [14C]-thymidine uptake, presumably by decreasing DNA 
synthesis. Clofarabine was also found to induce apoptosis of a solid tumor cell line, a 
finding which may open new fields of application of this drug. 
In paper II, 5’-nucleotidases, a family of enzymes known to confer resistance to 
nucleoside analogues, were found to be expressed at various levels in samples from 
CLL patients. Moreover, degradation of fludarabine monophosphate was found to be 
associated with CN2 activity, and degradation of cladribine monophosphate was 
associated with CN1 activity. This result helps to explain why some leukemic patients 
may show resistance to different nucleoside analogues.   
In paper III, we screened the RPMI 8226 myeloma cell line and its multidrug resistant 
subline 8226/Dox40 for the response to 3,000 chemically diverse compounds. We 
found one compound, designated VLX40, which showed strong cytotoxicity to the 
drug resistant cells. VLX40 was found to be cytotoxic to myeloid and lymphoid 
leukemia cells. Mechanistic studies showed that VLX40 is a novel microtubule 
inhibitor. The efficacy of the compound may potentially be improved leading to the 
development of novel tubulin active agents that are insensitive to common mechanisms 
of cancer drug resistance. 
  b-AP15 is a novel small molecule inhibitor of the ubiquitin-proteasome system. b-
AP15 inhibits the USP14/UCHL5 deubiquitinases of the 19S proteasome and shows 
anti-tumor activity in a number of tumor models. In paper IV, we examined the anti-
multiple myeloma activity of b-AP15. We found that b-AP15 has significant efficacy in 
multiple myeloma (MM) disease models, including cells resistant to the proteasome 
inhibitor bortezomib. The finding provides the framework for clinical evaluation of 
USP14/UCHL5 inhibitors to improve patient outcome in MM. In paper V, we show 
that despite the fact that b-AP15 is a reversible enzyme inhibitor, it induces rapid 
commitment to apoptosis/cell death. We show that the compound is rapidly taken up 
and enriched in cells, findings that explain the difference in potency of b-AP15 in 
biochemical and cellular assays. 
Based on the effective anti-cancer activity of b-AP15, we performed a lead 
optimization procedure aimed to identify efficient b-AP15 analogues with improved 
solubility. In paper VI, we identified the analogue VLX1570 which has similar 
biochemical activity as b-AP15. VLX1570 has strong antineoplastic activity in multiple 
myeloma cells and is capable of overcoming bortezomib resistance. We conclude that 
VLX1570 is a promising candidate for the clinical management of multiple myeloma. 
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1. BACKGROUND 
 
1.1 What is cancer? 
  
   Cancer is not a single disease, but a term used to describe hundreds of diseases [1]. It 
is characterized by either uncontrolled cell growth and/or prolonged survival of cells. 
Cancer may originate from almost any type of tissue and cancer cells may spread to 
distant tissues [2]. It is mainly induced by interaction of genetic susceptibility and 
environmental factors [3, 4]. In 2012, the estimates of the World Health Organization 
(WHO) for global cancer incidence and associated mortality were 14.1 million and 8.2 
million, respectively. In Sweden, 57,726 individuals were diagnosed with cancer in 
2011 [5]. Furthermore, it is estimated that > 1,665,000 new cancer cases and > 585,000 
cancer deaths will occur in the United States during 2014 [6]. In the United Kingdom, 
one person in three will develop a malignancy by the time they reach the age of 70 [7]. 
Although cancer can affect all ages, there is a steep increase in incidence with age.  
      The hallmarks of cancer include eight biological capabilities acquired during the 
multistep development of human tumors: sustaining proliferative signalling, evading 
growth suppressors, resistance to cell death, replicative immortality, induction of 
angiogenesis, activation of the propensity to invade and metastasize, reprogramming of 
energy metabolism and evasion of immune destruction [8]. A major problem in the 
clinical management of cancer is that malignant cells are not confined to their tissue of 
origin, but can spread to other parts of body via the lymphatic system and bloodstream, 
creating secondary deposits known as ‘metastases’ [9-11]. 
    Loss of cell cycle regulation and loss of regulation of cell death induction are central 
features in the etiology of the cancer and will be briefly reviewed below.  
 
Cell cycle 
   Non-dividing cells are in G0 phase. Cells reproduce by a series of well orchestrated 
events where cellular macromolecular contents are duplicated, followed by division 
into two daughter cells. Dividing cells pass through four distinct phases during the cell 
cycle (Figure 1): (1) the G1-phase where cells increase in size and prepare to copy their 
DNA; (2) the S-phase during which DNA is replicated (S for DNA synthesis); (3) the 
G2-phase during which cells further grow; (4) M-phase when chromosomes separate 
and cells divide (M for mitosis). After one cycle, the daughter cells can continue to 
enter a new cycle, enter G0 phase or become terminally differentiated [12, 13]. 
 
Cell death 
   According to morphological appearance of cells, cell death is mainly classified 
apoptosis and necrosis [14]. 
 
Apoptosis  
   Apoptosis, programmed cell death, is a fundamental process that occurs during 
development and is required for maintenance of tissue homeostasis. Deregulation of 
apoptosis may lead to diseases such as neurodegenerative disorders, diabetes, or cancer 
[15]. Apoptosis is an active, energy requiring process involving a characteristic series 
of morphological changes that accompany the degradation of the cell. Early features of  
apoptosis include chromatin condensation, DNA fragmentation and cell shrinkage. 
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Figure 1. Cell cycle: potential targets for chemotherapeutic drugs. 
 
During the late stages of apoptosis, cellular components are packed into apoptotic 
bodies which are phagocytised by macrophages and neighbouring cells, thus avoiding 
an inflammatory response [16]. Cytotoxic anticancer agents and radiotherapy induce 
mutations in cancer cells that may not be directly lethal, but the damage induces 
signaling events which trigger apoptosis.   
 
     There are two main pathways which trigger apoptosis: death receptor (extrinsic) and 
mitochondrial (intrinsic) pathways. The death receptor pathway is triggered when a 
extracellular death ligand (e.g. FasL) binds to a death receptor (e.g. Fas) on the cell 
surface, which in turn recruits the adaptor protein FADD (FAS-associated death 
domain) to form a complex called the death-inducing signalling complex (DISC). DISC 
then recruits and activates the initiator procaspase-8. Activated procaspase-8 
subsequently triggers a caspase cascade where downstream executioner caspases such 
as caspase-3 and caspase-7 are activated, ultimately leading to DNA fragmentation and 
apoptotic cell death [17]. The mitochondrial pathway can be triggered by a variety of 
cellular stresses (e.g. DNA damage, hypoxia, depletion of survival factors and ER 
stress), which can lead to release of molecules such as cytochrome c, apoptosis 
inducing factor (AIF) and Smac/DIABLO from mitochondria. When cytochrome c is 
released into the cytosol, it associates with Apaf-1 to form the apoptosome, a complex 
that activates procaspase-9. In the presence of cytochrome c and the nucleotide 
dATP/ATP, procaspase-9 is auto-catalytically activated and then induced downstream 
executioner caspases, such as caspase-3 and caspase-7 [18]. Smac/DIABLO (and 
probably Htra2/Omi) binds to/inhibits the inhibitors of apoptosis proteins (IAPs), a 
different class of caspase inhibitors (Figure 2) [19].  
     The Bcl-2 family of proteins plays an important role in the apoptosis. The Bcl-2 
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family comprises both proapoptotic and antiapoptotic members, the balance of which 
determines apoptosis. These proteins are regulating cytochrome c release from 
mitochondria. Upregulation of antiapoptotic Bcl-2 family proteins such as Bcl-2 and 
Bcl-xL and/or loss of function of proapoptotic proteins such as BAX and BAK is 
common in many human tumors. Dysregulation of the Bcl-2 family of proteins can 
prevent cell death in response to a variety of apoptotic stimuli. In mammals, the Bcl-2 
family consists of at least 20 members, all of which share at least one conserved Bcl-2 
homology (BH) domain [20]. Proapoptotic proteins, such as BAX and BAK, act mainly 
at the mitochondrion and are believed to induce the permeabilization of the outer 
mitochondrial membrane allowing efflux of cytochrome c [21]. Antiapoptotic members 
block apoptosis by guarding mitochondrial integrity and thus prevent the release of 
cytochrome c, as well as other mitochondrial molecules (Smac/DIABLO and 
Omi/Htra2) [22-24].  
 
Figure 2. A schematic illustration of the death receptor and mitochondrial pathways 
for apoptosis. The detailed description refers to the main text. 
 
Necrosis 
     The morphological features of necrosis are swollen organelles, plasma membrane 
rupture and loss of intracellular materials. Necrosis is usually caused by gross cell 
injury and severe cellular ATP depletion. It is thought as an accidental form of cell 
death in response to supra-physiological conditions. However, some studies have 
suggested that necrosis may also be tightly controlled and initiates either inflammatory 
or reparative responses in the host [25, 26]. 
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1.2 Cancer treatment 
    
    Current cancer therapies include four major types: surgery, radiotherapy, 
chemotherapy and immunotherapy. Surgery has a highest chance to achieve a complete 
cure. But surgical removal of the primary tumor is not always successful, due to 
irregular shape of some tumors, the inaccessibility of some tumors (e.g. brain tumors) 
or poor health and old age of the patients [27-29]. Furthermore, many tumors have 
metastasized at the time of diagnosis, leading to widespread disease which is no longer 
treatable by surgery. If surgery is not a good choice, other therapies must be 
considered. Radiotherapy has been used to the treatment of cancer for a hundred years. 
Ionizing radiation deposits energy that injures or destroys cells in the target tissue by 
damaging their genetic material, making it impossible for these cells to continue to 
grow [30-33]. Although radiation damages both cancer cells and normal cells, the latter 
are able to repair themselves and function properly. Radiotherapy may be used to treat 
localized solid tumors and some hematologic malignancies. Chemotherapy uses drugs 
to inhibit the proliferation of cancer cells or, preferably, to destroy cancer cells. Drugs 
are distributed via the vascular system and will be able to target both the primary tumor 
as well as any cancer cells that have spread to distant tissues [34]. Chemotherapy can 
be given orally, subcutaneously, intravenously, directly into a body cavity or topically 
applied to the skin. Immunotherapy uses the immune system to fight disease. This can 
be done by stimulating the patients' own immune system or by administering immune 
system components. Immunotherapy is also a systemic therapy [35]. These different 
types of therapies are often combined during clinical management of cancer. Reducing 
cancer morbidity and mortality still requires prevention and earlier detection. 
 
1.3 Principles of cancer chemotherapy 
    
   Chemotherapy can be used alone, but is usually used in combined therapy modalities, 
along with surgery and/or radiotherapy, to achieve and maintain remission. Both single 
agent and combination chemotherapy are given at intervals in pulsed doses or in cycles. 
The patients are monitored during the process in order to evaluate response to therapy, 
and treatment is adjusted accordingly. The complexity of the disease leads to 
considerable heterogeneity between patients with regard to response, leading to the 
necessity to individualize therapy according to tumor and patient characteristics. Large 
effort are being made in the fields of pathology, oncology and pharmacology to 
individualize therapy [34].   
   The aim of chemotherapy is to completely eradicate disease. Tumors nevertheless 
commonly relapse, and such relapses may occur locally or at a distance (metastasis) 
from the primary tumor site. Chemotherapy is usually classified as follows:  
(1) Induction chemotherapy: initial therapy administered with the aim of achieving 
significant reduction and ideally complete remission of the disease. The outcome may 
be a complete or partial response; 
 (2) Consolidation/intensification chemotherapy: administered after remission with the 
aim to prolong disease-free survival. Consolidation chemotherapy uses the same drugs 
for induction of remission;  
(3) Adjuvant chemotherapy: administered in combination with localized treatment such 
as surgery or radiotherapy; 
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(4) Neoadjuvant chemotherapy: given prior to local therapy with the aim to reduce 
tumor burden prior to surgery; 
(5) Maintenance chemotherapy: continuous, low-dose chemotherapy is used to extend 
the duration of remission and with curative intent; 
(6) Salvage chemotherapy: may be given after failure of other treatments to control the 
disease and/or to provide palliation; 
(7) Combination chemotherapy: although single agent chemotherapy may be used in 
some situations, combination chemotherapy achieves more profound effects on tumors 
[36]. 
    Most chemotherapeutic drugs target the process of cell proliferation and division to 
explore since cancer cells divide at higher frequency than normal cells. [12, 37].  
 
1.4 Classification of chemotherapeutic agents 
 
   Since the discovery of the toxic action of nitrogen mustards on blood cells [38], many 
chemotherapeutic agents have been discovered by screening the cytotoxic potency of a 
large number compounds in vitro or in vivo models. They are generally classified 
according to their mechanism of action as described below. 
 
1.4.1 Alkylating agents 
   This class of agents include nitrogen mustards, alkyl alkane sulphonates, nitrosureas, 
tetrazines, and platinum agents. They cause cell death by cross-linking DNA strands, 
which may result in inhibition of DNA, RNA and (ultimately) protein synthesis. This 
type of drugs are cell cycle-nonspecific agents [39, 40]. 
 
1.4.2 Antimetabolites 
   Antimetabolites have structural similarities to natural existing substances, such as 
vitamins, nucleosides or amino acids. They mainly comprise folic acid antagonists, 
pyrimidine analogues and purine analogues. They usually act by competing with 
natural substrates for the active site on key enzymes or receptors. Some antimetabolites 
are incorporated directly into DNA or RNA, resulting in inhibition of DNA, RNA and 
protein synthesis. Most of them are cell cycle-specific agents [41-43].  
 
1.4.3 Anti-microtubule agents 
     Vinca alkaloids and taxoids are the two main groups of anti-microtubule agents. 
Although both types of agents cause microtubule dysfuction, resulting in blocking of 
cell division, they have opposite mechanisms of action. The vinca alkaloids prevent the 
formation of the microtubules, whereas taxoids prevent microtubule disassembly [44, 
45].   
  
1.4.4 Topoisomerase inhibitors 
      There are two broad classes in topoisomerase inhibitors: topoisomerase I inhibitors 
and topoisomerase II inhibitors. Topoisomerases are involved in all DNA-dependent 
events, such as DNA replication, transcription, recombination, repair and nucleosome 
remodelling, chromosome condensation and segregation [46]. Inhibition of 
topoisomerase activity results in induction of DNA strand breaks, resulting in inhibition 
of cell proliferation and/or apoptosis. This class of drugs are phase-specific and prevent 
cells from entering mitosis [47]. 
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1.4.5 Cytotoxic antibiotics 
    Most cytotoxic antibiotics are derived from bacteria and fungi. They have various 
mechanisms of action. This group of drugs include anthracyclines, actinomycin, 
bleomycin and mitomycin c. They affect the function and synthesis of nucleic acids in 
various ways [12, 42]. 
   In addition to the above classes of chemotherapeutic agents, there are a number of 
miscellaneous agents that target different points of cell growth pathways, and that may 
induce cell death. 
   In this thesis, I have studied a few different chemotherapeutic agents: nucleoside 
analogues, anti-microtubule agents and proteasome inhibitors.  
 
1.5 Resistance to chemotherapeutic agents 
 
     Drug resistance remains as a major obstacle for the effectiveness of chemotherapy. 
Cancer drug resistance includes two broad categories: intrinsic and acquired. Intrinsic 
resistance is a term used to describe the fact that tumor cells may show natural 
resistance to certain therapies due to expression of factors that interfere with therapy 
efficacy. Acquired drug resistance means that tumor cells that are initially sensitive to 
drugs become resistant due to mutations and various adaptive responses during the 
process of treatment [48, 49].  
    Tumor cells are constantly selected for survival and proliferation [50]. In general, 
cancer cells develop drug resistance due to the mechanisms outlined below (Figure 3):  
 
1.5.1 Drug influx and drug efflux 
    Both decreased drug uptake and increased drug efflux can induce drug resistance. 
Drug efflux is mediated by the ATP-binding cassette (ABC) transporter family. Three 
members of this family are associated with multidrug resistance (MDR): ABCB (also 
known as ABCB1/MDR1/P-glycoprotein), the MDR-associated protein 1 (MRP1; also 
known as ABCC1), and breast cancer resistance protein (BCRP; also known as 
ABCG2/MXR). All three proteins have broad and overlapping substrate specificity and 
promote the elimination of various hydrophobic compounds [48]. MDR1 is a 
membrane-bound glycoprotein that is expressed in most tissues. MDR1 is also 
overexpressed in many tumors and can also be induced by chemotherapy. Many studies 
have shown that overexpression of MDR1 is associated with chemotherapy failure in 
various types of cancer [51-53]. MRP1 overexpression is also associated with drug 
resistance in lung, breast and prostate cancer [54-56] and BCRP is identified to 
correlate with chemo-resistance in breast cancer and leukaemia [57, 58]. 
 
1.5.2 Drug activation and inactivation 
    Resistance mechanisms related with drug metabolism are usually specific for each 
class of drugs. Nucleoside analogues (NAs) can be inactivated by deoxycytidine kinase 
(dCK) which catalyse the rate-limiting step of conversion of most NAs to their 
corresponding monophosphates. Decreased or absent dCK activity will therefore confer 
resistance to NAs [59-63]. Platinum drugs and alkylating agents can be inactivated by 
glutathione [64], and the conversion of antimetabolites such as 5-fluorouracil (5-FU) 
and methotrexate to their active forms does not occur when the relevant cellular 
enzyme activities are absent [65, 66]. 
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1.5.3 Alterations in drug targets 
     Mutation or alteration of the expression of a drug target can reduce the effectiveness 
of inhibitors of the target, leading to resistance. For example, mutation and/or 
overexpression of the gene encoding proteasome subunit β5 (PSMB5) lead to 
resistance to the proteasome inhibitor bortezomib [67]. Similarly, alterations in MAPK 
and mutation of MEK1 or/and MEK2 have been shown in patients with acquired 
resistance to RAF or MEK inhibitor monotherapy [68]. 
 
1.5.4 Adaptive response 
   After active drug has accumulated and inhibited its target(s), the effectiveness of 
treatment depends on how the cancer cell responds. Many anticancer drugs act via 
inducing DNA damage, directly or indirectly. The cell may respond to DNA damage in 
two ways: by repair or cell death. The response of cancer cells to DNA damage is a 
major factor determining the effectiveness of DNA-damaging drugs. Examples are 
deficiencies or mutations in mismatch repair (MMR) genes or/and p53, which may 
confer resistance to DNA damaging drugs [48, 50]. 
 
1.5.5 Deregulation of apoptosis 
   Mutations, amplifications, chromosomal transactions and overexpression of anti-
apoptotic proteins, such as anti-apoptotic BCL-2 family members, inhibitor of 
apoptosis proteins (IAPs) and the caspase 8 inhibitor FLIP, are also associated with 
resistance to chemotherapy [48-50]. Moreover, these genes may also be transcriptional 
targets for prosurvival transcription factors, for example nuclear factor-κB (NF-κB) and 
signal transducer and activator of transcription 3 (STAT3), the expressions of which are 
frequently activated during tumorigenesis [48]. 
 
 1.5.6 Autophagy 
    Autophagy is a lysosomal degradation pathway that degrades damaged organelles 
and proteins in order to maintain cellular biosynthesis and viability under conditions of 
metabolic stress [14, 69]. Although autophagy has been shown to play a clear role in 
tumor suppression, its role during cancer treatment is still controversial. The ability of 
autophagy to promote cell survival during nutrient deprivation and other types of stress 
suggests that it may promote resistance to cytotoxic therapy. Many studies have indeed 
shown that tumor cell autophagy induced by anticancer treatment inhibits tumor cell 
killing [53, 70, 71].  
    
    In this thesis, we identified a novel tubulin active agent insensitive to common 
multidrug resistant models. Multiple drug resistance (MDR) describes a phenomenon 
whereby resistance to one drug is accompanied by resistance to several drugs 
completely differing in chemical structure and/or mechanism of action. It is a major 
factor in the failure of many forms of chemotherapy. In the clinic, the problem of MDR 
can include two main types: one acquired during treatment and the other pre-existing at 
the time of diagnosis. The identification of mechanisms of MDR is important for 
development of therapeutic agents to overcome the MDR. In addition to the 
mechanisms discussed above, the concept that the proliferation of human tumor may be 
driven by a minor population of self-renewing tumor cells, often termed tumor stem 
cells, may be of large importance for MDR. Tumor stem cells with MDR properties 
may repopulate tumors between cycles of cancer therapy, representing a major problem 
in clinical oncology [72, 73]. 
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Figure 3. Cellular mechanisms of drug resistance. 
The anticancer activity of a drug can be affected by poor drug uptake or/and excessive 
drug efflux, drug inactivation or limited activation, mutations or alterations of 
expression of drug targets, activation of adaptive prosurvival responses and 
dysfunctional apoptosis that block cell death [48]. 
 
1.6 Nucleoside analogues  
    
   The effectiveness of nucleoside analogues (NAs) as antitumor drugs was established 
in the 1960’s with the nucleobase antimetabolites 5-fluorouracil [74] and the 
thiopurines [70]. These agents mimic physiological nucleosides in terms of uptake and 
metabolism and are incorporated into newly synthesized DNA, resulting in synthesis 
inhibition and chain termination. Some NAs can also inhibit key enzymes involved in 
the generation of purine and pyrimidine nucleotides and RNA synthesis, and some can 
directly activate the caspase cascade. In addition, these compounds may potentiate their 
action by indirectly inhibiting ribonucleotide reductase (RR), thus lowering the 
availability of endogenous nucleosides [75, 76]. All of these effects may lead to cell 
death [75].  
    Nucleoside analogues are transported into the cell either by active transport via 
specific transporters, including nucleoside transporters such as hCNT and hENT, or by 
passive diffusion. Once they have entered into cells, NAs are phosphorylated to mono-, 
di- and triphosphate forms by the enzymes dNK, NMPK and NDPK, respectively 
(Figure 4). The action of these enzymes is counteracted by cytoplasmic 5’-nucleotidase 
activity which can dephosphorylate monophosphate derivatives. NAs can also be 
rapidly deaminated by cytidine deaminase to non-toxic metabolites [75]. Most 
nucleoside analogues exert their cytotoxic effects by interfering with DNA replication 
with their active form. Although NAs share common general characteristics, each drug 
also has specific properties in terms of drug-target interactions, which helps to explain 
the variation in their efficacies toward different diseases. 
    The NA family includes both pyrimidine and purine analogues. During the past 
decades, new NA agents have been introduced into clinical use. Furthermore, the use of 
NAs has expanded into the field of solid tumors. 
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Figure 4. Schematic presentation of metabolism and mechanisms of action for NAs. 
NAs enter cells via specific nucleoside transporters. Once inside the cells, NAs are 
phosphorylated by dNK, NMPK and NDPK to the active triphosphates. 5’-NTs can 
dephosphorylate 5-monophosphate derivatives, preventing the production of the active 
forms. NAs exert their action by inhibition of DNA synthesis resulting in chain 
termination and cell death. Also, some NAs indirectly block DNA replication by 
inhibiting the RR enzyme, leading to reduced production of deoxyribonucleotide 
diphosphates (dNDPs). The decrease of deoxyribonucleotides triphosphate (dNTP) 
pools favors incorporation of NA active 5-triphosphate derivatives into DNA to block 
DNA synthesis. Furthermore, NA-triphosphates can directly activate the caspase 
cascade by stimulating apoptosome formation.  
 
1.6.1 Purine nucleoside analogues 
Cladribine (2-chloro-2’-deoxyadenosine, CdA) 
    Cladribine is a deoxyadenosine analogue [77]. Cladribine received FDA approval in 
the 1980s for treatment of hairy cell leukaemia [78]. CdA has activity in a variety of 
hematologic malignancies, autoimmune conditions and multiple sclerosis [79-86]. It 
was recently shown that in addition to its purine nucleoside analogue activity, 
cladribine possesses epigenetic properties, by inhibiting S-adenosylhomocysteine 
hydrolase (SAH) and DNA methylation [87-92].  
   CdA is phosphorylated to CdATP by dCK, AMP kinase, and nucleoside diphosphate 
kinase. In mitochondria, it is phosphorylated by dGK [93]. CdAMP can be 
dephosphorylated by 5’-NTs. The accumulation of CdATP has been shown to depend 
on the relative concentrations of dCK and 5’-NTs [94]. CdA is cytotoxic both to 
replicating and resting cells [95, 96]. In replicating cells, it inhibits DNA synthesis by 
incorporation of its triphosphate form into DNA [97, 98], resulting in chain termination 
and S-phase-specific apoptosis [99]. CdA also inhibits DNA replication indirectly 
through inhibition of ribonucleotide reductase [100]. In addition, CdA can disrupt the 
integrity of mitochondria [101], leading to the release of the pro-apoptotic 
mitochondrial protein, thereby initiating the caspase cascade. Moreover, CdATP can 
cooperate with cytochrome c and Apaf-1 to activate caspase-3 and trigger the caspase 
pathway [102, 103]. In resting cells, CdATP is incorporated into DNA by the repair 
machinery and terminates the nucleotide excision repair process leading to the 
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progressive accumulation of DNA single-strand breaks which eventually initiate 
apoptosis by p53-dependent or p53-independent pathways [104, 105]. Incorporation of 
CdA into DNA may also alter gene transcription with a consequent depletion of 
proteins required for cell survival [106]. 
 
Fludarabine (9-β-D-arabinosyl-2-fluoroadenine, Fara-A) 
   FaraA is a purine (adenosine) nucleoside [107]. Fludarabine has been extensively 
used in lymph proliferative malignancies, including various types of non-Hodgkin’s 
lymphoma [108]. 
   Similar to other NAs, it requires phosphorylation to Fara-ATP for interruption of 
DNA and RNA synthesis and induction of apoptosis [109, 110]. Similar to CdA, Fara-
A is cytotoxic to both dividing and resting cells. In dividing cells, it inhibits DNA and 
RNA synthesis and RR. DNA synthesis inhibition is mediated by competition of the 
triphosphate metabolite with dATP for incorporation into DNA [111]. RR inhibition 
causes a reduction of dNTPs pools. The mechanism of action of Fara-A in replicating 
cells is mainly cell cycle-specific, and incorporation of Fara-ATP into DNA during S 
phase is required for the induction of apoptosis [112]. In resting cells, FaraA can block 
cellular DNA repair. In addition, Fara-AMP and Fara-ATP can be incorporate into 
RNA, resulting in premature termination of the RNA transcript, impairing its function 
as a template for protein synthesis [113]. Fara-ATP also inhibits RNA synthesis by 
suppressing the activity of RNA polymerase II [114]. Fara-ATP is also a nucleotide 
activator of Apaf-1, with the consequent activation of the caspase-9 and caspase-3 
pathways. Moreover, it was reported that Fara-A downregulate Bcl-2 mRNA 
expression, thereby favouring apoptosis [115].  
 
Clofarabine (2-chloro-2’-fluoro-deoxy-9-β-D-arabinofuranosyl adenine, CAFdA) 
    Clofarabine, a second-generation purine nucleoside analogue, was designed to 
overcome the limitations of fludarabine and cladribine [116]. Similar to other 
nucleoside analogues, clofarabine enters cells by nucleoside transporters. Once 
clofarabine is transported into the cell, it is phosphorylated to its monophosphate 
derivatives by deoxycytidine kinase (dCK) or deoxyguanosine (dGK), a process that is 
counteracted by dephosphorylation by 5’-nucleotidases. CAFdA-monophosphate is 
further phosphorylated to its active form, clofarabine triphosphate [117]. CAFdA-
triphosphate is effective against proliferating, quiescent and resting cells and is a potent 
inhibitor of DNA polymerase-α and -ε [118]. In addition, the action of CAFdA-
triphosphates may involve RNA-dependent mechanisms [119-121]. CAFdA-
triphosphate also strongly inhibits RR activity. Furthermore, CAFdA-triphosphate can 
replace dATP and directly affects cytosolic apoptotic protease-activating factor 1 
(Apaf-1), then leading to caspase activation [102]. CAFdA-triphosphate also has direct 
actions on mitochondria leading to the release of proapoptopic factors, such as 
cytochrome c and apoptosis-inducing factor, to activate pro-apoptotic pathways [122].  
    Clofarabine was approved by the United States Food and Drug Administration for 
treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia 
(ALL) in 2004, and by the European Commission in 2006 [123]. With the rapid 
development of clofarabine in hematologic malignancies, the anti-cancer activity of 
clofarabine toward other types of tumors has attracted interest. 
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1.6.2 Pyrimidine nucleoside analogues 
Cytarabine (1-β-D-arabinofuranosylcytosine, cytosine arabinoside, cytarabine, araC) 
   Cytarabine is a pyrimidine nucleoside-based anticancer drug widely used for the 
treatment of leukemia [124]. It may be used alone or in combination with other 
anticancer agents, such as daunorubicin, doxorubicin, thioguanine, or vincristine [124]. 
     In the cell, ara-C is phosphorylated by dCK and pyrimidine kinases to the active 5-
triphosphate derivative ara-CTP [125, 126] to inhibit DNA polymerase by competing 
with deoxycytidine triphosphate and thus reduce the cell replication [125]. Cytarabine 
acts on rapidly dividing cells and inhibits DNA synthesis at the S-phase of the cell 
cycle and also hinders progression of cells from the G1-phase to the S-phase. 
 
Gemcitabine (2’, 2’ -difluoro 2’ deoxycytidine, dFdC) 
    Gemcitabine is a pyrimidine analogue [127]. Gemcitabine is effective in inhibiting 
the growth of human neoplasms and is used for the treatment of a broad range of solid 
and hematological cancers.  
   Gemcitabine first requires cellular uptake by nucleoside transporters and is then phos-
phorylated to dFdCMP by dCK. The monophosphate form is subsequently converted 
dFdCDP and dFdCTP by pyrimidine kinases. The cytotoxic activity of gemcitabine is 
thought to related to inhibition of DNA polymerase and the incorporation of the drug 
into DNA [128], leading to the termination of chain elongation [129]. The dFdCDP 
metabolite also inhibits RR, resulting in a decrease in competing deoxyribonucleotide 
pools necessary for DNA synthesis. Additionally, dFdCTP incorporates into RNA, 
although the consequences of this incorporation has not been extensively studies [127].  
 
1.6.3 Metabolism of nucleoside analogues 
 
Anabolic enzymes 
   This family of enzymes is involved in two pathways: the de novo pathway and the 
salvage pathway. 
 
Deoxycytidine kinase (dCK) 
     dCK is expressed throughout the cell cycle. The activity of dCK can be increased by 
exposure to deoxyribonucleoside, NAs, genotoxic agents and UV/γ-irradiation [130-
134]. dCK is highly expressed in quiescent cells where it phosphorylates nucleosides 
necessary for DNA repair and the expression may, depending on the cell type, increase 
several-fold when the cells enter S-phase [135-138]. dCK is believed to be the most 
important enzyme for activation of NAs due to its high expression in hematopoietic 
cells [139]. Low enzyme activity can lead to resistance to NAs [140-143].   
 
Deoxyguanosine kinase (dGK) 
   dGK shows sequence homology with dCK [144]. dGK is mainly located in 
mitochondria, but can be translocated into the cytosol during apoptosis. Mitochondrial 
dGK is responsible for phosphorylation of purine deoxyribonucleosides and their 
analogues in the mitochondrial matrix, providing the dNTPs necessary for 
mitochondrial DNA synthesis. Cytoplasmic dGK may also contribute to the supply of 
purine deoxynucleotides for nuclear DNA replication and repair. Nucleoside analogues 
phosphorylated by dGK may therefore exert their cytotoxic effects by interference with 
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both mitochondrial and nuclear DNA synthesis [75].  
 
Thymidine kinase-1 (TK1) 
    TK1 plays an important role in the pyrimidine salvage pathway. The expression of 
TK1 is regulated following the cell cycle, high-level expression during S-phase. TK1 is 
expressed in leukemia cell lines and numerous malignant tumors [145]. Some 
important nucleoside analogues, such as zidovudine (AZT), stavudin and floxuridine, 
can be phosphorylated by TK1 [146, 147]. 
 
Thymidine kinase-2 (TK-2) 
     TK-2 is a mitochondrial enzyme which is expressed in all tissues and throughout the 
cell cycle, being the only pyrimidine deoxyribonucleoside kinase expressed in non-
proliferating cells [148]. TK-2 has a broad substrate specificity, phosphorylating dCyt, 
thymidine and dUrd It also phosphorylates anti-cancer and anti-viral NAs such as AZT, 
Ara-C and dFdC [149]. In humans, deletion of the TK-2 gene leads to a myopathic 
form of mitochondrial DNA depletion syndrome [150].  
 
Catabolic enzymes 
 
5’-Nucleotidase (5’-NT) 
  This family of enzymes dephosphorylates nucleoside monophosphates and cytotoxic 
mononucleotides. In vitro, increased 5’-NT activity has been consistently associated 
with nucleoside drug resistance [62, 96, 151].  
 
Cytosolic 5’-nucleotidase-1 (CN1) 
   CN1-A is located in the cytosol and expressed at a high level in brain, skeletal and 
heart muscle [152]. This enzyme has a broad range of substrates, AMP and pyrimidine 
deoxyribonucleotides, and also for monophosphates of adenosine, cytidine and 
guanosine [153]. When CN1-A over-expressed in the cells, the cells become less 
sensitive to several NAs. CN1-B shows the highest expression in testis and lowest 
expression in skeletal muscle and the brain. CN1-A and CN1-B show sequence 
homology and have similar substrate specificities [154]. 
 
Cytosolic 5’-nucleotidase-2 (CN2) 
    CN-2 is ubiquitously expressed in human tissues. CN-2 has been reported to have 
high activity in lymphoblastoid cells [155]. Downregulation of CN-2 using siRNA 
results in significantly decreased sensitivity of patient cells to NA treatment [156] and a 
high CN-2/dCK ratio is associated with NA resistance both in the leukemic patients 
[157] and in cell lines [158, 159].  
 
Cytosolic 5’ (3’)-deoxyribonucleotidase-1 (dNT1) 
    dNT1 is ubiquitously expressed in human tissues [160]. The enzyme uses all 
deoxyribonucleotide monophosphates except deoxytidine monophosphate as substrates 
[161]. Low levels of dNT1 may increase cellular concentrations of dCTP to compete 
with the triphosphates of active cytidine analogues resulting in decreased cytotoxic 
effects [162]. 
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Cytosolic 5’ (3’)-deoxyribonucleotidase-2 (dNT2) 
      dNT2 has a similar structure as dNT1. The mRNA level of dNT2 is high in brain, 
heart and skeletal muscles and low in kidney and pancreas. dNT2 shows specificity for 
dUMP and dTMP. In non-cycling cells with minimal de novo synthesis, the dNT2/TK2 
substrate cycle is important for regulation of dTTP pools [163]. 
 
Ecto-5’-nucleotidase 
     Ecto-5’-NT gene is expressed in many tissues and is frequently expressed in acute 
leukemia [164, 165]. The enzyme dephosphorylates purine mononucleotides to 
nucleosides, commonly AMP to adenosine. 
 
Cytidine deaminase (CDD) 
    Cytidine deaminase catalyses the inactivation of cytidine and dCyd to uridine and 
deoxyuridine, respectively. CDD also deaminates some NAs, i.e. ara-C and gemcita-
bine [166]. Several studies have indicated that increase levels of CDD is associated 
with the development of resistance to ara-C [167-169].  
 
1.6.4 Ribonucleotide reductase 
   Human ribonucleotide reductase (RR) plays a vital role in the synthesis of the four 
deoxyribonucleosides required for DNA synthesis and repair by catalyzing ribonucleo-
side diphosphates to deoxyribonucleoside diphosphates [170]. This rate-limiting step in 
synthesis of DNA precursors is regulated at several different levels, including allosteric 
control of activity and specificity of RR by nucleoside triphosphates [171]. RR is a 
tetramer composed of two non-identical homodimers, designated R1 and R2. 
Transcription of the R2 gene occurs exclusively during the S-phase [172], whereas R1 
is virtually constant throughout the cell cycle.  When R2 is not available, R1 will 
associate with p53R2 to form active RR that supplies quiescent cells with 
deoxyribonucleotides for repair of damaged DNA [173, 174].  
 
1.7 Tubulin inhibitors 
 
   Tubulin inhibitors are an important class of anticancer agents. Since the first known 
compound binding tubulin, colchicine, was identified, a large number of tubulin-
binding agents have been isolated or synthesized and used for cancer treatment.   
 
1.7.1 Tubulin and the microtubule system 
 
Microtubulin structure and function 
    The structural backbones of microtubules are tubulin dimers and microtubule 
associated proteins (MAPs). There are 5 forms of tubulin: α-, β-, γ-, δ- and epsilon-
tubulin [175, 176]. α- and β-tubulin are the main subunits of microtubules. Both α-and 
β-tubulin contain binding sites, the N- and E-sites, for the nucleotide guanosine 
triphosphate (GTP). One GTP molecules is tightly bound to the α-tubulin and cannot 
be exchanged, while another GTP molecule is bound to β-tubulin and can be free to 
exchange with guanosine diphosphate (GDP) [45, 177]. Microtubules grow from 
discrete assembly sites in the cells called microtubule organizing centers (MTOCs), 
which are a network of MAPs. MAP is a complex family of proteins, including MAP2, 
MAP4, Mip-90, tau and STOP, most of them are related with regulation of tubulin 
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polymerization and function [45, 177].  
    The process of microtubule formation includes three phases: nucleation, elongation 
and steady state. Nucleation is the slow formation of a small microtubule nucleus 
from soluble tubulin. Following formation of this nucleus, microtubules rapidly 
elongate. Elongation involves the rapid addition of heterodimers to the plus end of the 
microtubule. After elongation, the microtubule enters a steady state. Lengthening and 
shortening of the microtubule are balanced in steady state [178]. 
    Microtubules are essential components of the cytoskeleton of eukaryotic cells and 
play important roles in key cellular functions such as cell signaling, proliferation, cell 
shape and structure maintenance, formation of mitotic spindles, intracellular migration 
and transport [177]. Furthermore, microtubules are associated with the permeability 
transition pore that is involved in cytochrome c release during apoptosis [45].  
 
1.7.2 Mechanism of action of microtubulin inhibitors 
    Because the microtubule system is important for cell division, development of 
anticancer agents that target microtubule dynamic has become an attractive strategy. 
According to the mode of action and binding site, tubulin inhibitors can be classified 
three groups: taxane-like microtubule stabilizing compounds, vinca alkaloid site 
binding agents and colchicine site binding agents [45].  
    Tubulin inhibitors act via interfering with the microtubule polymerization or 
depolymerization. Depolymerization inhibitors suppress microtubule dynamics by 
induction of polymerized tubulin, enhancement of microtubule assembly and increasing 
the microtubule polymer mass at high concentration in the cells. They act as 
microtubule-stabilizing agents, and are referred to as "depolymerization inhibitors". An 
example is paclitaxel (Taxol®). MT polymerization inhibitors include colchicine 
binding site inhibitors and vinca alkaloids binding site inhibitors. Both of them bind to 
β-tubulin. This class of inhibitors suppresses microtubule dynamics by causing 
microtubule depolymerization. They act as microtubule-destabilizing agents, and are 
referred to as  "polymerization inhibitors". Examples are colchine analogues and vinca 
alkaloids [179-182].  
                  
Paclitaxel 
    Paclitaxel was initially isolated from the bark of the yew tree Taxus brevifolia 
[180]. In 1979, Schiff and Horwitz found that paclitaxel causes microtubule 
stabilization and increased polymer mass [183]. Paclitaxel has been found to be of 
clinical benefit for the treatment of breast, ovarian, skin, head and neck and non-small 
cell lung carcinomas [184]. Paclitaxel can directly bind to β-tubulin of MTs, which 
result in the stabilization of the lateral interactions between heterodimers. This leads 
to inhibition of mitosis, chromosome segregation, and cell division [182, 185].  
 
Vincristine 
    Vincristine was first isolated from the leaves of the periwinkle plant Catharanthus 
roseus. It was approved by the US FDA in 1963 as Oncovin. As a tubulin inhibitor, 
vincristine is mainly used in children leukemia, adult hematological malignancies and 
nephroblastoma [186]. It is also occasionally used as an immunosuppressant. 
Vincristine directly binds to the β-subunit of the tubulin dimer near the exchangeable 
nucleotide. Vincristine blocks microtubule assembly and induces microtubule 
depolymerization, prevents GTP hydrolysis and decreases polymer [179]. These 
mechanisms induce the arrest of mitosis in the metaphase [177, 182]. 
     Based on the properties of many of the currently used tubulin inhibitors, 
development of new antimicrotubule agents is an active field of research.  
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1.8 Proteasome inhibition  
     Intracellular protein turnover is essential for the regulation of cellular functions and 
maintenance of cellular homeostasis. Two major protein degradation systems are used 
by cells: the lysosomal system and the ubiquitin-proteasome system (UPS) [187]. More 
than 80% of the degradation of cellular proteins was estimated to be preformed by the 
UPS [188]. Tumor cell growth and survival are dependent on the ubiquitin proteasome 
pathway (UPP) and the development of compounds that target the UPP is attracting 
increasing interest from cancer drug pharmacologists.   
 
1.8.1 Ubiquitin-proteasome pathway (UPP) 
     The critical role of the UPP in biology was recognized by Avram Hershko, Aaron 
Ciechanover and Irwin Rose, who were awarded with the Nobel Prize for Chemistry in 
2004. The UPP is the major system for protein degradation in the mammalian cytosol 
and nucleus. It is involved in a broad variety of cellular processes, including apoptosis, 
cell cycle regulation, DNA transcription and repair, antigen presentation, cell 
differentiation and protein quality control [189-191]. Defects in the UPP can result in 
the pathogenesis of several important human diseases, such as neurodegenerative 
disorders, viral diseases and cancer [192]. 
   UPP includes two discrete and successive processes: (i) tagging of the substrate 
protein by the covalent attachment of a polyubiquitin chain (conjugation); (ii) the 
subsequent degradation of the tagged protein by the 26S proteasome (degradation) 
(Figure 5).   
 
Figure 5. Ubiquitin proteasome pathway. 
 
1.8.1.1 Ubiquitination 
    Ubiquitin (Ub) is a tightly packed globular protein consisting of 76-amino acids 
which is strongly expressed in cells [193]. Ubiquitination is a posttranslational 
modification that depends on the sequential action of three enzymes: ubiquitin 
activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3). 
The human genome encodes two isoforms of E1, dozens of E2 enzymes and more than 
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1000 types of E3 ligases. The different types of E3 ubiquitin ligases confer specific 
substrates to the UPP [194].  
   Ubiquitination of target protein is performed in three steps. First, ubiquitin is 
activated by the formation of a thiol ester bond between its C-terminal glycine residue 
and an active site cysteine residue in the E1 enzyme. Secondly, the activated ubiquitin 
molecule is transferred to an active cysteine residue of an E2 enzyme to generate a new 
thiol ester intermediate. Finally, E3 ligases catalyze the transfer of ubiquitin from the 
E2 to a lysine residue of a target protein. Following the addition of the first ubiquitin to 
the substrate, the process is repeated by attachment of additional ubiquitin monomers, 
resulting in the formation of a polyubiquitin chain (Figure 6) [195, 196]. Most 
substrates require polyubiquitination to be delivered to the proteasome. Ubiquitin 
chains can be formed on one or more of the seven lysine residues of ubiquitin at 
position 6, 11, 27, 29, 33, 48 and 63, resulting in ubiquitin chains of various lengths, 
types and functions. Lys48-linked chains represent the most abundant ubiquitin chain 
type in human cells (~ 28%) [197]. They are required for protein degradation by the 
proteasome. Recent studies show that Lys6, Lys11, Lys27, Lys29, and Lys33 linked 
chains are also involved in proteasomal degradation of proteins [198]. Lys63-linked 
chains are associated mainly with non-proteolytic processes such as transcription, 
intracellular protein trafficking, autophagy, DNA-damage response and cell signalling. 
[199-202]. Recently, Lys63-linked chains were also shown to be targets for proteasome 
degradation [203-205]. Ubiquitination can be reversed by specific deubiquitinating 
enzymes (DUBs). Deubiquitination can occur at any time after addition of ubiquitin to 
a target substrate, regulating protein stability [206]. 
 
Figure 6. The process of ubiquitination. 
 
   Most proteasomal substrates bind to ubiquitin receptors on the proteasome. The 
enzyme ornithine decarboxylase (ODC), a key role in the polyamine biosynthesis, is an 
exception to this rule. Instead of binding poly-ubiquitin chains, ODC is degraded by the 
proteasome via binding of polyamine-induced protein (antizyme) [207, 208]. 
 
1.8.1.2 26S proteasome 
     The 26S proteasome is a large multicatalytic enzyme complex and found in nucleus 
and cytosol of all eukaryotic cells. It consists of a central 20S core particle (CP) capped 
with one or two 19S regulatory particles (RP) [209, 210]. 
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    The 19S regulatory particle plays multiple roles in regulating the activity of the 
proteasome including recognition of ubiquitinated substrate and deubiquitination, 
substrate unfolding and translocation into the 20S catalytic chamber [211]. The 19S RP 
is composed of at least 19 subunits with molecular masses ranging from 10 to 110 kDa 
and can be divided into two sub-complexes: the base and the lid [212].  
    The base includes six AAA+ ATPases, Rpt1/S7, Rpt2/S4, Rpt3/S6, Rpt4/S10b, 
Rpt5/S6 and Rpt6/S8, which form a ring structure [213]. The base also includes four 
non-ATPase subunits: Rpn1/S2, Rpn2/S1, Rpn10/S5a and Rpn13/hRpn13 [213-216]. 
The ATPases provide the energy required for substrate unfolding, necessary for enter of 
substrates into the 20S CP catalytic chamber. Rpt2/S4 is involved in the process of 
opening of the pore into the 20S CP and Rpt5/S6 plays a role in recognizing poly-
ubiquitin chains [217-219]. In the base, Rpn1/S2 and Rpn2/S1 are the largest subunits 
of the proteasome [220, 221]. Most substrates dock at the proteasome by binding 
specific ubiquitin receptors. Rpn1/S2 binds ubiquitin receptor-like Rad23, Dsk2 and 
Ddil, members of the UBL-UBA family. These proteins contain an ubiquitin-like 
(UBL) domain that can bind to Rpn1, Rpn10 and Rpn13 in the proteasome and one or 
more ubiquitin associated (UBA) domains which bind to poly-ubiquitinated chains 
[222]. UBL-UBA proteins have been proposed to function as shuttling factors that 
selectively deliver polyubiquitinated substrates to the proteasome [223]. Rpn10/S5a 
and Rpn13/hRpn13 are two ubiquitin receptors located in the base of the 19S RP. They 
bind ubiquitin chains. Rpn10/S5a contains two C-terminal ubiquitin-interacting motifs 
(UIM), which cooperate in binding multiple ubiquitins in chains [220, 224]. Rpn13 has 
high affinity to bind Lys48-linked di-ubiquitin and serves as a receptor for the 
Uch37/UCHL5 deubiquitinating enzyme, linking chain recognition and disassembly 
[225]. 
   The lid complex includes 9 non-ATPase subunits, Rpn3, Rpn5–Rpn9, Rpn11, Rpn12, 
and Sem1 [212]. The connection of the lid complex and the base complex is via 
interactions between Rpn12 and Rpn2, and between Rpn11 and Rpn1 [226].  
   A major task of the lid and the base is deubiquitination. Rpn11/S13  (also referred to 
as POH1) is the essential DUB for this function and other two additional DUBs also 
participate the deubiquitination process, UCH37/UCHL5 and Ubp6/USP14. While 
Rpn11/S13 promotes substrate degradation, UCH37/UCHL5 and Ubp6/USP14 are 
belived to antagonize substrate degradation. These latter DUBs trim the polyubiquitin 
chain from the distal end to regulate the time of substrate-proteasome interaction and 
then the rate of degradation [227-229]. 
   The 20S core particle is a degradation unit which is made up of four stacked rings, 
forming a central cavity. Seven different α subunits form the two outer rings, the main 
structure, and cap the two inner rings which contain seven different β subunits [230]. 
The catalytic activities of the proteasome are divided into three major classes: the 
caspase-like, trypsin-like, and chymotrypsin-like activities. These activities are 
associated with the β1, β2, and β5 subunits, respectively, and confer the ability to 
cleave peptide bonds at the C-terminal side of acidic, basic, and hydrophobic amino-
acid residues [191]. The three peptidase activities can be probed using specific 
fluorogenic peptides. Proteasome inhibitors have been developed that target these 
activities [231]. The channel leading into the catalytic chamber is narrow (~ 13 Å in 
diameter) and is mainly composed of α2, α3 and α4 subunits. In order to be degraded 
into oligopeptides, substrate proteins pass this narrow channel to access the active sites 
of catalytic enzymes at the center of the α-ring [232-234].  
 
1.8.1.3 Deubiquitinating enzymes of the 26S proteasome 
    Like many other protein modifications, ubiquitylation is a reversible process The 
conjugated polyubiquitin chains are removed and cleaved by deubiquitinases (DUBs) 
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to facilitate substrate translocation and degradation. The human genome encodes at 
least 98 DUBs that are divided into six classes: the ubiquitin C-terminal hydrolases 
(UCHs), ubiquitin-specific proteases (USPs), ovarian tumor proteases (OTUs), 
Machado-Joseph disease protein domain proteases, JAMM/MPN domain-associated 
metallopeptidases (JAMMs) and monocyte chemotactic protein-induced protein 
(MCPIP) families. All of these enzymes are cysteine proteases, with the exception of 
the JAMM/MPN+ DUBs which are zinc metalloproteases [235]. Deubiquitination is 
carried out by the hydrolysis of the isopeptide bond in ubiquitin–protein conjugates.        
Three DUBs are associated with the proteasome: Rpn11/POH1, Ubp6/USP14 and 
Uch37/UCHL5 (yeast/human nomenclature).  
 
Rpn11/POH1 
    Rpn11/POH1 is a Zn2+-dependent DUB that belongs to the JAMM domain family 
and is a part of the lid of the 19S RP [236]. Rpn11 is essential for substrate degradation 
during the process of deubiquitination. Rpn11/POH1 is localized above the entrance to 
the ATPase ring. This location is beneficial for the subsequent removal of ubiquitin 
from substrates prior to translocation of the substrate into the CP. Rpn11 cleaves the 
ubiquitin chain in an ATP-dependent manner. To avoid disassembly from the receptor 
during the cleavage process, an ubiquitin chain must consist of least four ubiquitin units 
to span the distance between the receptors and the Rpn11 [227, 237, 238]. Defects of 
Rpn11/POH1 block cell growth, cellular protein degradation and the assembly of the 
26S proteasome, resulting in the inhibition of the activity of the proteasome [239, 240]. 
Rpn11/POH1 is essential for viability of cancer cells, but detailed mechanistic studies 
in the proteasome context are lacking due to difficulties in purification, which has 
prevented the development of potent inhibitors for Rpn11 [241]. Lys63-linked poly-
ubiquitin chains are the preferable substrates for Rpn11/POH1[242].  
    Rpn11/POH1 is an obvious target for development of anticancer agents [243]. 
Knockdown of Rpn11/POH1 has same effect as proteasome inhibition, leading to the 
accumulation of polyubiquitinated substrate proteins [240, 243]. Overexpression of 
Rpn11/POH1 confers cellular resistance to vinblastine, doxorubicin and paclitaxel, 
possibly via modulation of AP-1-mediated stress pathways [244]. Rpn11/POH1 can 
also increase the expression of ErbB2, a receptor tyrosine kinase which is associated 
with poor prognosis in breast cancer [245]. 
 
Ubp6/USP14 
   Ubp6/USP14, a cysteine protease, is a member of the ubiquitin specific proteases 
(USP) family. Lys-48-linked poly-ubiquitin chains are the preferable substrates for 
Ubp6/USP14 and are cleaved from their distal end or within the chain [240]. Unlike 
Rpn11/POH1, Ubp6/USP14 is not an integral subunit of the proteasome. The full-
length human Ubp6/USP14 contains 494 amino acids, with a 9-kDa UBL domain at its 
N-terminus followed by a 45-kDa catalytic domain, which resembles an extended right 
hand comprised of three domains: fingers, palm, and thumb. These three domains form 
a binding surface for ubiquitin. Two surface loops, blocking loop 1 and 2 (BL1 and 
BL2), partially fill the predicted binding pocket for the C-terminus of ubiquitin. These 
loops are believed to block access of the C-terminus of ubiquitin to the active site of 
USP14 and the BL2 and BL1 loops must be removed for enzymatic activity [246, 247]. 
Ubp6/USP14 catalytic activity is increased several hundred-fold when it is associated 
with the proteasome and it can be dissociated from the proteasome under high-salt 
conditions [228, 240].  
   Ubp6/USP14 is believed to be involved ubiquitin recycling. Deficiency of ubiquitin 
pools impairs the function of the UPP, resulting in protein accumulation [248-250]. 
    Ubp6/USP14 has also been shown to inhibit proteasome activity in a manner 
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independent of its DUB activity by delaying the breakdown of proteins by the 
proteasome. Proteins are docked at the proteasome for a longer time, which leads to 
more extensive trimming of ubiquitin chains, thus reduces the affinity of protein to the 
proteasome [248, 251]. The interaction of Ubp6/USP14 and ubiquitin conjugates also 
can stimulate gate opening of the 20S core particle, enabling the substrate to be 
degraded [252].The majority of the cellular content of Ubp6/USP14 is not associated 
with the proteasome, indicating that the enzyme may be involved in other cellular 
processes [252]. 
   High expression of USP14 has been found in several hematopoietic and solid tumor 
cell lines, for example leukemic, colon cancer and multiple myeloma cells [253-255]. 
The overexpression of Ubp6/USP14 was reported to be beneficial for cell proliferation 
via induction of β-catenin and was found to be correlated with overall survival rate of 
lung adenocarcinoma and colorectal cancer patients [256]. 
 
Uch37/UCHL5 
    Uch37/UCHL5 is a cysteine protease and a member of ubiquitin C-terminal 
hydrolases (UCH) family. Uch37/UCHL5 can cleave both Lys48- and Lys63-linked 
poly-ubiquitin chains [257]. Similar to the Ubp6/USP14 enzyme, it is associated with 
the base complex of the 19S RP and reversibly associates with the proteasome. The 
estimated molecular mass of UCHL5 is 37.6 kDa [258]. It includes two functional 
domains, a catalytic domain (UCH-domain) and a C-terminal domain. In distinction to 
Rpn11/POH1, Uch37/UCHL5 is not essential for the activity or the structure of the 26S 
proteasome. It can bind to 26S proteasome via the Rpn13/Admr1 receptor located in 
the 19S RP base complex. Uch37/UCHL5 suppresses proteasome degradation through 
disassembly of distal polyubiquitin chains and releases mono-ubiquitin from chains 
[238, 259, 260]. A recent study has shown that Uch37/UCHL5 promotes the 
degradation of specific proteasome substrates, nitric oxide synthase and IκB-α [261]. 
Above indicates that Uch37/UCHL5 suppresses or promotes proteasome degradation 
may differ between substrates. UCHL5 has also been shown to associate with the Ino80 
chromatin-remodeling complex in the cell nucleus, which is related with nucleosome 
position during transcription or DNA repair [262]. Both knockdown of USP14 and 
UCHL37 can block cell growth, decrease protein degradation and accumulate 
polyubiquitinated proteins [240]. 
    The activity of UCHL5 was also found to be increased in several carcinomas, 
including cervical carcinoma, hepatocellular carcinoma and multiple myeloma [255, 
263-265]. UCHL5 was reported to affect cell survival via its interaction with Smad7, a 
transcription factor involved in transforming growth factor-β (TGF-β) signaling [266, 
267].  
 
1.8.2 Cellular responses to proteasome inhibition 
    As the proteasome plays essential role in the cell function, the proteasome inhibitors 
as therapeutic agents attracted more and more attention. Proteasome inhibitors exert 
broad effect on cancer cells by various mechanisms to induce cell death in many types 
of tumors. 
 
NF-κB 
     NF-κB is a transcription factor induced by various signals, such as pathogens, 
growth factors and cytokines [268]. NF-κB regulates various immune and 
inflammatory responses, cell survival and proliferation. NFκB is constitutively active in 
a large proportion of advanced cancers to promote tumor cell growth, and NFκB 
overexpression has been linked to resistance anticancer drugs [269]. NFκB is activated 
via proteasomal degradation of its inhibitor IκB. Proteasome inhibitors inhibit NF-κB 
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activity by preventing degradation of IκB, resulting in tumor cell apoptosis [270, 271]. 
However, the role of NFκB in mediating the effects of proteasome inhibition is 
controversial [191]. One study showed that proteasome inhibitors actually activate 
NFκB in endometrial carcinoma cells [272]. Another report showed that the 
proteasome inhibitor bortezomib can activate two upstream NFκB activating kinases 
(RIP2 and IKKβ) in multiple myeloma cells, promoting non-proteasomal degradation 
of IκB and increases NFκB DNA binding [273]. In addition, some reports also 
suggested that NF-κB activity enhances tumor cell sensitivity to apoptosis. NF-κB 
transcriptionally up-regulated pro-apoptotic target genes, for example p53 and Bax, 
leading to induce cell death [274-276]. However, one study showed that NF-κB is not 
involved in the response of HCT-116 cells to bortezomib [277]. 
 
Cell cycle 
   Progression through the cell cycle is tightly controlled by regulatory proteins which 
are degraded in UPP. Three key classes of regulatory molecules are included in the 
process of the cell cycle: cyclins, cyclin-dependent kinases (CDKs) and cyclin-
dependent kinase inhibitors (CKIs) [278]. Proteasome inhibitors induce cell cycle arrest 
by blocking the degradation of cyclins (D, E, A, B) and cell cycle regulatory proteins 
and accumulation of CKIs (p21 and p27) in malignant cells [279-281].  
  
Regulation of apoptosis 
    Inhibition of proteasome activity leads an upregulation of proapoptotic factors such 
as p53, pro-apoptotic members of the Bcl-2 family (Bax, Bak, Bad, Bim, Bik, and Bid) 
and NOXA, and to downregulation of anti-apoptotic proteins such as Bcl-2 and IAP 
(inhibitor of apoptosis) proteins [282].  
    The tumor suppressor p53 is an important regulator of apoptosis induced by DNA 
damage and transforming oncogenes. p53 is regulated by interaction with its negative 
regulator Mdm-2, which is an E3 ubiquitin ligase. In cancer cells, Mdm-2 is often over 
activated, leading to proteasomal degradation of p53 [283-285]. Proteasome inhibition 
can upregulate p53 and activate p53 downstream target genes such as p21, Fas ligand, 
PUMA and Bax to block cell growth and induce apoptosis [286].  
 
Endoplasmic reticulum stress (ER stress) 
    Inhibition of proteasome can induce accumulation of unfolded or misfolded proteins 
in ER lumen leads to induction of ER stress [287]. In order to cope with the stress, cells 
elicit a signal network termed unfolded protein response (UPR). The goal of the UPR is 
to restore ER homeostasis and promote cell survival. However, if proteasome inhibitors 
maintain accumulation of misfolded proteins, signalling can switch from pro-survival 
to pro-apoptotic [288]. Tumor cells usually have higher protein synthesis rates than 
their normal counterparts, leading them more prone to accumulation and aggregation of 
protein and more sensitive to proteasome inhibitor-induced apoptosis. Induction of pro-
apoptotic ER stress by proteasome inhibitors has been found in different cancer cell 
types including, multiple myeloma, head and neck cancer and non-small cell lung 
carcinoma [289, 290]. 
 
Oxidative stress 
    Oxidative stress reflects an imbalance between the production of reactive oxygen 
species (ROS) and antioxidant defences [291]. Superoxide anions, hydrogen peroxide, 
and hydroxyl radicals all have higher reactivity than molecular and can severely 
damage DNA, protein, and lipids [292]. ROS is mainly produced by the electron 
transport chain in the mitochondria [293]. Antioxidant defences include enzymatic 
antioxidant defenses (superoxide dismutase, catalase, glutathione peroxidase, 
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thioredoxin reductase) and non-enzymatic antioxidants (Vitamin C, Vitamin E and 
others) [294, 295]. 
        Proteins oxidation may lead to misfolding and aggregate formation [296]. The 
UPP can remove oxidized proteins [297]. Moreover, oxidized proteins can be degraded 
by the 20S CP in an ATP-independent manner without involvement of ubiquitin [298]. 
Elevated level of ROS can increase p53 expression and in induction of the JNK 
pathway, resulting in induction of apoptosis [299]. Usually tumor cells have higher 
levels of ROS than normal cells in order to promote cell survival and tumor progression 
[189]. Proteasome inhibitors have been shown to induce ROS in various cancer cells 
[300-303].  
 
DNA repair 
    Proteasome inhibitors may affect DNA repair by the depletion of available nuclear 
ubiquitin [304]. Inhibition of proteasome activity leads to accumulation of non-
degraded polyubiquitinated proteins and a reduction in the amount of free ubiquitin. A 
decreased ubiquitin pool will result in a decrease in histone ubiquitination, and 
impaired DNA-damage responses. Proteasome inhibitors have been proved to sensitize 
tumor cells to various anticancer therapies such as radiation, camptothecin and 
topoisomerase inhibitors, all of which induce DNA damage [191]. 
 
1.8.3 Inhibitors of the ubiquitin proteasome pathway 
 
Bortezomib 
     Bortezomib (PS-341, Velcade ®; Millennium Pharmaceuticals) was chosen from a 
series of boronic acid analogues screened against the National Cancer Institute’s 
(NCI’s) panel of 60 cancer cell lines, according to its potency of cytotoxicity [305]. 
Bortezomib was extensively studied in vitro and in vivo in several tumor types, 
including non-small cell lung cancer, prostate cancer, multiple myeloma and mantle 
cell and follicular non-Hodgkin’s lymphoma. Bortezomib was found to show 
particularly strong cytotoxic activity against multiple myeloma. It was approved for 
third-line treatment of multiple myeloma by the FDA in 2003 [306], and was later 
approved for first-line treatment and for treatment of mantle cell lymphoma [307]. 
Bortezomib is a reversible inhibitor of the chymotryptic-like and caspase-like activities 
of the 20S CP [308]. Many researches have bee shown that bortezomib can induce 
growth arrest and apoptosis in a wide range of tumor cell lines, animal models or/and 
patients of hematologic and solid tumor malignancies by the different mechanism of 
proteasome mentioned above. Such as, the inhibition of the NF-κB activation[309], 
induction of p53 [310], and the CKIs p27 and p21 [311], activates the stress kinase 
JNK, and induces pro-apoptotic proteins [312, 313]. However, as I mentioned above, 
there are conflicting reports concerning the role of NF-κB activation [314]. Bortezomib 
not only shows considerable activity as a single agent, but shows additive/synergistic 
activity in combination with other chemotherapeutic agents [296, 315]. The activity of 
bortezomib might not entirely be due to proteasome inhibition. Thus, when proteasome 
subunit expression was knocked-down using siRNA, bortezomib still induced an 
increase in the number of apoptotic cells without a further reduction in proteasome 
activity [279]. But similar to other chemotherapeutic agents, acquired drug resistance 
and serious side effects limit the efficacy of bortezomib in clinical use. The toxic side 
effects of bortezomib include peripheral neuropathy, low platelet and erythrocyte 
counts and joint pain [266]. Large efforts are devoted to the development of new 
proteasome inhibitors, with the goal to overcome bortezomib resistance, reduce 
toxicity, enhance anti-tumor activity and improve effectiveness of proteasome 
inhibition. 
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A new generation of proteasome inhibitors 
    Carfilzomib, a second generation of proteasome inhibitor, is an irreversible inhibitor 
of the chymotrypsin-like activity of the proteasome [316]. In clinic, marizomib has 
been shown the activity on bortezomib-refractory multiple myeloma patients and is 
well tolerated with no peripheral neuropathy side effects [317]. In addition, new 
generation of proteasome inhibitors such as NPI-0052, MLN9708, CEP-18770 and 
ONX0912 have been shown to show activity on bortezomib-resistant cells, extending 
the range of application and enhancing clinical outcomes [191].  
 
Targeting deubiquitinating enzymes 
    The importance of DUBs for proteasomal degradation have fueled interest in these 
enzymes as targets for anticancer agents [318]. A number of pan-DUB inhibitors 
targeting both proteasomal and non-proteasomal DUBs have been described. WP1130 
(degrasyn), a small-molecule DUB inhibitor, can inhibit USP9X, USP5, USP14 and 
UCHL5. By inhibiting these DUBs, WP1130 treatment leads to accumulation of poly-
ubiquitinated proteins, down-regulation of anti-apoptotic mediators and up-regulation of 
pro-apoptotic proteins in cells [319]. WP1130 has shown antitumor activity in lymphoma 
animal models [320]. IU1 is a reversible small molecule inhibitor of USP14. At high 
concentrations, IU1 increases the degradation of proteasome substrates. Since IU1 
increases proteasome activity, this compound is not a candidate for anticancer drug 
development. However, it has been suggested as a treatment option for neurodegenerative 
diseases that are associated with the accumulation of misfolded and aggregated proteins 
[251]. AC17 is a curcumin analogue which has been shown to irreversibly inhibit the 
deubiquitinase activity of the 19S RP. The anticancer activity of AC17 was investigated 
both in vitro and in vivo and is associated with the inhibition of NF-κB and activation of 
p53. However, the specificity of AC17 with regard to DUBs inhibition is unclear[321]. b-
AP15 is a novel small molecular reversible inhibitor of the proteasomal DUBs USP14 
and UCHL5. It was found to have antineoplastic activity in a number of tumor models 
representing both hematological and solid tumor [322]. b-AP15 was demonstrated to be 
cytotoxic to bortezomib resistant cells [255].  
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2. AIMS 
      The overall purpose of this thesis was to examine the phenomenon of anticancer 
drug resistance and to identify and characterize drugs that are effective on tumor cells 
that have acquired resistance to conventional cancer therapy.  
 
 
Specific aims: 
 
! To investigate the effect of clofarabine on apoptosis and DNA synthesis in 
human epithelial colon cancer cells. 
 
! To measure 5’-NT activities and CdAMP and Fara-AMP degradation in 
samples from patients with chronic lymphocytic leukemia and to investigate the 
relationship between the levels of dCK mRNA and the cytotoxicity of five 
nucleoside analogues (dFdC, CdA, FaraA, Ara-C and CAFdA). 
 
! To identify novel active agents insensitive to multidrug resistance by drug 
screening. 
 
! To investigate the action of the deubiquitinase inhibitor b-AP15 in multiple 
myeloma and the ability of this drug to overcoming bortezomib resistance. 
 
! To investigate the cellular uptake and metabolism of b-AP15 and to further 
characterize its mechanism of action. 
 
! To perform lead optimization of b-AP15 and to evaluate the activity of the 
optimized lead VLX1570 in multiple myeloma. 
 
 
 24 
3. RESULTS AND DISCUSSION 
3.1 Paper I: Effect of Clofarabine on Apoptosis and DNA Synthesis in Human 
Epithelial Colon Cancer Cells 
 
      Clofarabine, a new-generation purine nucleoside analogue, has shown significant 
efficacy in pediatric relapsed/refractory acute lymphoblastic leukemia (ALL) and 
hematologic malignancies in adults. Based on its broad activity, the effect of 
clofarabine on the DNA synthesis of human colon carcinoma cells (HCT116) was 
investigated in this study.  
     
     We used a LigandTracer White instrument to investigate the uptake and retention of 
clofarabine in cells. At 100 nM, the uptake is detectable and at 10 µM a strong signal is 
achieved and approaches equilibrium after 1∼2 hours. Thymidine incorporation into 
cells (and presumably DNA) was rapidly stopped by incubation with 10 µM 
clofarabine and a 3-fold increase in apoptosis induction in HCT116 cells by clofarabine 
was detected. 
     
     The results show that clofarabine is capable of inducing apoptosis of solid tumor 
cells, presumably due to interference with DNA synthesis. The experimental approach 
to drug uptake in real-time was found to be quite useful and was also used in paper V.   
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3.2 Paper II: 5’-Nucleotidase activities in blood cells from untreated patients with 
B-cell chronic lymphocytic leukemia: Correlation to the efficacy of nucleoside 
analogue therapy 
    The primary aim of this study was to uncover the significance of 5’-NT activities for 
the sensitivity of chronic lymphocytic leukemia (CLL) cells to nucleotide analogues. 
We measured the activities of 5’-NTs in peripheral blood cells from 59 CLL patients by 
using HPLC-based procedures. Considerable inter-individual variations in the activity 
of different 5’-NTs were observed. The median value of CN1 was 132 pmol/mg 
protein/min (95% CI=119-157), the median value of CN2 activity was 478 pmol/mg 
protein/min (95% CI=427-616) and median dNT activity was 3265 pmol/mg 
protein/min (95% CI 2690-3573). A clear relation between the degradation of 
fludarabine monophosphate (Fara-AMP)	   and cytosolic CN2 activity was observed, 
and a relation between the degradation of cladribine monophosphate and CN1 
activity. Although Fara-AMP and CdA have similar chemical structures and 
mechanisms of action, there are also some important differences, especially with 
respect to the enzymes involved in their metabolism [323, 324]. These differences 
may explain why certain CLL patients who experienced relapse with Fara-AMP 
treatment may still respond to CdA [325-327] as previously described [328, 329]. The 
results suggest that treatment with different NAs can be individualized. 
   Although the role of 5’-nucleotidases in resistance to NAs has not yet been 
extensively investigated, observations using cell lines as well as clinical studies have 
indicated that these enzymes are important in decreasing the clinical efficacy of NAs 
[330, 331]. For instance, an Ara-C-resistant cell line with a high level of CN2 and 
reduced level of dCK was found to be less sensitive to FaraA compared to another 
cell line, which only had a low level of dCK [332]; a series of K562 cell lines 
resistant to dFdC, CdA, Ara-C and Fara-A exhibited elevated CN2 and low dCK 
activities [333]; elevated levels of CN2 mRNA were found to be correlated with poor 
prognosis for patients with acute myeloid leukemia (AML) [334, 335]; high levels of 
CN2 mRNA and low levels of CN3 mRNA were found to be correlated with poor 
clinical outcome for AML patients treated with Ara-C [336]; dCK and CN2 mRNA 
expression in leukaemic blasts at diagnosis is correlated with clinical outcome and 
may play a functional role in the resistance to ara-C in patients with AML[337]; low 
levels of dCK, dNT1 and ecto-NT mRNA and over-expression of hCNT3 mRNA 
have been found to be correlated with more rapid disease progression in patients with 
CLL receiving Fara-AMP [338] and among patients with CLL or hairy cell leukemia, 
non-responders exhibited higher CN2 and /or lower dCK activity [339].  
   By phosphorylating nucleoside analogues, dNKs oppose the action of 5’-NTs and 
are therefore likely to play an important role in determining dNTP pool sizes. We 
found that the sensitivity of leukemic MOLT4 cells to purine analogues was 
attenuated by down-regulation of dCK using siRNA (Figure 7, 8). Thus, the efficacy 
of cladribine and fludarabine treatment in CLL may be dependent on the level of 
cellular dCK, CN1 and CN2 activities. In conclusion, the expression of anabolic and 
catabolic enzymes may be of important to consider in predicting the response to CLL 
treatment. 
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Figure 7. The effects of siRNA transfection on levels of dCK and 5’-NT mRNA in 
MOLT4 cells. Cells were transfected with siRNA designed to silence dCK or one of 
various 5’-NT genes, and mRNA levels subsequently measured. The levels obtained 
were normalized to the levels of housekeeping GAPDH mRNA and are expressed as 
percent down-regulation in comparison to control cells transfected with non-specific 
siRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  The sensitivities of siRNA-transfected cells to nucleoside analogues.  
Cell transfected with siRNA designed to silence the expression of 5’-NTs (dNT1, CN1 
and CN2) or dCK were incubated for 24 hours with one of five purine analogues, 
dFdC, CAFdA, Fara-A, CdA or AraC. The results are expressed as percent apoptotic 
cells in comparison to the control cells transfected with non-specific siRNA (NS).  
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3.3 Paper III: Screening for phenotype selective activity in multidrug resistant 
cells identifies a novel tubulin active agent insensitive to common forms of cancer 
drug resistance 
         
     Drug resistance is a major obstacle to successful treatment of many cancers. This 
study was designed to identify drugs effective on multidrug resistant cells.  
 
A well characterized MDR model was used, the multidrug resistant myeloma cell 
line RPMI 8226/Dox40. This cell line was originally selected for resistance to 
doxorubicin and show cross-resistance to mitoxantrone, acronycine, etoposide, and 
vincristine. The resistant subline strongly overexpresses the MDR1 gene product P-
gp170. Screening a library of 3,000 chemically diverse compounds resulted in the 
identification of a compound, designated VLX40, which demonstrated slightly higher 
activity against 8226/Dox40 cells compared to its parental counterpart. We found that 
VLX40 inhibited proliferation of the breast cancer cell line MCF7 and induced 
apoptosis in myeloma and myeloid leukemia cell lines. In order to understand the 
molecular mechanisms of action, we used a bioinformatic approach based on drug-
specific gene expression signatures [340]. The results suggested that VLX40 was a 
tubulin-active agent; in vitro assays subsequently confirmed that VLX40 inhibits the 
polymerization of tubulin monomers. VLX40 was also found to induce G2/M cell 
cycle arrest.  
 
    Several antitubulin drugs are in clinical use, such as palitaxel and vincristine. We 
found that VLX40 showed a favorable pharmacological profile compared to 
vincristine being active against a multidrug resistant myeloma cell line with little 
sensitivity to other common forms of vinca alkaloid resistance. In addition, VLX40 
showed a relatively narrow spectrum of activity in PCPTCs of various tumor types, 
particularly in leukemias and lymphomas. In contrast, vincristine is often insensitive 
to myeloid blast cells. Compared to its high activity in leukemias and lymphomas, 
VLX40 showed very limited activity on ex vivo solid tumor cells from breast, ovary, 
lung, colon and renal cancer patients. The reason for the low activity observed in the 
PCPTC solid tumor models may be due to a poor drug penetration in the latter model 
system, consisting of multicellular clusters. This hypothesis was supported by the 
modest antitumor activity obtained in the 3-D spheroid model cell line. In addition to 
poor penetration, low rates of proliferation of PCPTCs could contribute to the low 
solid tumor activity observed. 
    
    We also investigated the effect of VLX40 and six standard cytotoxic drugs on solid 
and hematological tumor samples, expressed as the solid/hematological (S/H) ratio. 
VLX40 had a ratio of 0.28 indicating a modest activity against solid tumors compared 
to cisplatin (S/H ratio 1.2). Other drugs showed S/H ratios < 0.5. The results for the 
standard drugs are consistent with their main clinical use. In addition, for evaluation 
of tumor cell specificity, drug effects were compared in cells from CLL and normal 
PBMCs. VLX40 expressed a significantly higher activity against malignant 
phenotypes with a PBMC/CLL median IC50 ratio of 12.2. Among the tested standard 
cytotoxic drugs only vincristine was more active in CLL than in PBMC. The high 
PBMC/CLL IC50 ratio indicates a potentially high therapeutic index. It should be 
considered that both the PBMC/CLL ratio and S/H ratios are in vitro indicators for 
therapeutic index and clinical activity spectra and should be evaluated in relative 
rather than absolute terms. A ratio of 1 indicates equal sensitivity for PBMC vs. CLL 
and solid vs hematological activity, respectively.  
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     In vivo activity of VLX40 was investigated in hollow fiber cultures of myeloid U-
937 cells subcutaneously implanted in mice.  
      
     VLX40, a 2-phenyl-4-hydroxyquinoline, is a flavone-like element that has 
previously been used in medicinal chemistry, for example to design inhibitors of 
bacterial cell membrane pumps [341] or to inhibit cyclo-oxygenases [342]. However, 
several studies have reported that 2-phenyl-4-quinolones, the isomers of 2-phenyl-4 
hydroxy-quinolines, have cytotoxic activities on human cancer cells [343-347]. The 
2-phenyl-4 hydroxy-quinolines are structurally unrelated with other tubulin inhibitors, 
and may have different characteristics of importance for cytotoxic activity and 
resistance. Vincristine is a substrate for both MRP and P-gp170, but VLX40 appears 
unaffected by both mechanisms. AML cells are relatively insensitive to vincristine, 
but are sensitive to VLX40. VLX40 may therefore be useful for development of 
novel tubulin active agents that are insensitive to common mechanisms of cancer 
drug resistance and an agent for AML. 
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3.4 Paper IV: A novel small molecule inhibitor of the deubiquitylating enzymes 
USP14 and UCHL5 induces apoptosis of multiple myeloma cells and overcomes 
bortezomib resistance 
 
     Proteasome inhibitors have shown antiproliferative activity in multiple myeloma by 
targeting protein degradation. In this study we found that b-AP15, a novel small 
molecular inhibitor of the USP14/UCHL5 DUBs of the 19S RP, decreases viability in 
MM cell lines and patient MM cells, inhibits proliferation of MM cells even in the 
presence of bone marrow stroma cells, and overcomes bortezomib resistance. 
       
     By western blotting and immunohistochemistry analysis, we found that USP14 and 
UCHL5 are highly expressed in MM cells compared to normal plasma cells and 
PBMCs. We also found that the knockdown of USP14 and UCHL5 can decrease MM 
cell viability. These finding suggested that USP14 and UCHL5 are required for 
viability of MM cells and that these enzymes are valid anticancer targets. 
     
   b-AP15 induced significant accumulation of polyubiquitin conjugated proteins in 
MM cells. b-AP15 did not inhibit the proteolytic activities of the proteasome and did 
not inhibit total DUB activity.  We observed inhibition of USP14 and UCHL5 
activity in treated cells using the active site probe ubiquitin vinyl sulphone. The 
results suggest that b-AP15 targets the deubiquitylating function of USP14 and 
UCHL5 in the cellular environment. It should be noted, however, that the efficacy of 
inhibition of particularly UCHL5 varied between experiments. We do not quite 
understand the reason for this variability, but believe it to be due to b-AP15 being a 
reversible inhibitor. During preparation of cell extracts for labeling experiments, the 
compound may detach from the target enzymes, perhaps by a temperature-dependent 
manner. 
     
   Peripheral neuropathy associated with bortezomib therapy is believed to partly 
result from blockade of the neuronal cell survival protease HtrA2/Omi. In this study, 
we found no significant inhibition of HtrA2/Omi in response to b-AP15 treatment, 
whereas bortezomib inhibited HtrA2/Omi activity. These data further suggested the 
selectivity of b-AP15. 
      
   We also found b-AP15 not only deceased viability in MM cell lines and primary 
MM cells from patients, but also had antitumor activity in distinct human MM 
xenograft models. At the IC50 for MM cells, of b-AP15 did not significantly affect 
the viability of normal PBMCs. In addition, we found that anti-MM activity of b-
AP15 is associated with growth arrest via downregulation of CDC25C, CDC2, and 
cyclin B1 as well as induction of caspase-dependent apoptosis, and activation of UPR 
signaling pathway. Importantly, ANBL-6 and its bortezomib-resistant subline ANBL-
6.BR showed similar sensitivities to b-AP15. We also found similar responses to b-
AP15 in tumor cells from patients in whom MM was resistant to therapies such as 
bortezomib, lenalidomide, and dexamethasone. These data suggest that b-AP15 (or 
related compounds) can be used for treatment of patients with bortezomib resistant 
MM.  
     
  We also examined anti-MM activity of b-AP15 in vivo. A significant inhibition of 
tumor growth was observed in two distinct human MM xenograft mouse models 
treated with b-AP15. In addition, b-AP15 treatment was not associated with any 
detectable toxicity as evidenced by no significant effects on body weight and/or 
alteration in blood chemistry. By IHC analysis of caspase 3 cleavage, Ki67, VEGF, 
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VEGFR2, LYVE1 and CD31in the tumor sections from tumors harvested from 
control and b-AP15–treated mice, we further confirm the anti-MM activity of b-AP15 
in vivo at aspect of apoptosis, proliferation and angiogenesis. 
    
     Finally, we also examined whether b-AP15 can be combined with other anti-MM 
agents. Our results show synergistic anti-MM activity of b-AP15 with HDAC 
inhibitor SAHA, dexamethasone and lenalidomide.  
 
     In summary, this study showed the efficacy of b-AP15 in MM disease models by 
targeting DUBs in the ubiquitin proteasomal cascade and had the ability to overcome 
proteasome inhibitor resistance, which provides the framework for clinical evaluation 
of USP14/UCHL5 inhibitors to improve patient outcome in MM. 
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3.5 Paper V: The 19S deubiquitinase inhibitor b-AP15 is enriched in cells and 
elicits rapid commitment to cell death 
 
    In this study we characterized several questions related to the molecular 
pharmacology of the b-AP15 compound.  
     
    b-AP15 contains an α, β-unsaturated carbonyl unit that is likely to serve as a 
Michael acceptor to interact with the thiol group of cysteines in deubiquitinating 
enzymes, leading to inhibition of deubiquitinase activity. b-AP15 contains an 
additional Michael acceptor (an acrylamide residue). We here tried to understand the 
relative roles of these Michael acceptors plays a role for the biological activity of b-
AP15. The acrylamide was not required for induction of cell death. In contrast, 
decreasing the reactivity of the unsaturated carbonyls lead to reduced cytotoxic 
effects. The result suggested that the biological activity of b-AP15 is governed 
primarily by the reactivity of α, β-unsaturated carbonyl pharmacophore.  
    
     The reversibility of b-AP15 was investigated in this study. We used the suicide 
probe Ub-VS to determine the activity of USP14 and UCHL5 and confirmed that 
both proteasomal DUBs are inhibited by b-AP15. Dilution of b-AP15 in cell extracts 
lead to recovery of the active USP14, indicating b-AP15 to be a reversible enzyme 
inhibitor. We were interested in determining whether inhibition of proteasome 
function and induction of apoptosis by b-AP15 would also be reversible. To address 
this question, we used a reporter cell line expressing a proteasome targeted substrate, 
ubiquitin fused to yellow fluorescent protein (UbG76V-YFP). Treatment of cells with a 
low concentration of b-AP15 for one hour resulted in the induction of polyubiquitin 
conjugates, which started to decrease after 4 hours from drug removal. A similar 
pattern was observed for the reporter protein UbG76V-YFP and the proteasome 
substrate p21Cip1, indicating that b-AP15 was a reversible inhibitor of proteasome 
function. Interestingly, cleavage of caspase-3 and PARP was observed 24 hour after 
drug removal, indicating that despite reversible inhibition of the proteasome function 
cells became committed to apoptosis after only one hour of b-AP15 exposure.  
 
    Using the LigandTracer® White technique (used in Paper I), we observed that b-
AP15 was rapidly uptaken by cells during ~30 min. After washing out of the drug, we 
found a ~40% decrease of the content of radiolabeled b-AP15 over two hours and a 
~50% decrease after ten hours. These findings suggested that drug is available for 
proteasome inhibition even washout after a short treatment with a high drug 
concentration. Consistent with this, treatment of reporter UbG76V-YFP expressing 
cells with a higher b-AP15 concentration resulted in the accumulation of poly-
ubiquitin conjugates that were still abundant after 8 hours from drug removal. In 
addition, we found low concentrations of free intracellular b-AP15, suggesting that 
majority of the drug molecules may bind to cellular macromolecules. As mentioned 
above, Michael acceptors react with thiol groups in cysteines of proteins, suggesting 
that b-AP15 was binding to intracellular thiols. We pretreated cells with N-
ethylmaleimide, a covalent inhibitor of DUB activity, before treatment of cells with 
radiolabeled b-AP15. Interestingly, the cellular uptake of b-AP15 was inhibited by 
pre-treatment 10 µM NEM. This result showed that uptake into cells was thiol-
dependent. Whether inhibition is due to inactivation of a thiol-dependent transport 
system, or due to NEM blocking a subset of hyper-reactive cysteines which also bind 
b-AP15, is not known at present. It appears likely that, similar to b-AP15, NEM is 
enriched intracellularly and may block a large fraction of reactive cysteines when 
used at 10 µM. 
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     Higher concentrations of b-AP15 were required to inhibit deubiquitinase activity 
in biochemical assays than in assays of proteasomal function on cells [322]. The 
reason for this difference was further investigated in this study. When Ub-AMC was 
used as a DUB substrate, an IC50 ~ 17 µM of b-AP15 was observed. The use of other 
substrates and assays resulted in somewhat lower IC50 values (~5 µM). This values 
are higher than the b-AP15 concentrations of < 1 µM that were sufficient to inhibit 
proteasome function in colon carcinoma cells. The reason for this apparent 
discrepancy appears to be the effective uptake of b-AP15 from the medium and 
enrichment of this compound in cells.  
     
     b-AP15 is expected not to only bind to thiols present in the proteasomal 
deubiquitinases, but also to other enzymes and proteins. We here found that b-AP15 
inhibits thioredoxin reductase. The thioredoxin enzymatic system is important for 
redox regulation of cellular function. The inhibition of thioredoxin reductase may 
help to explain the strong induction of oxidative stress observed by b-AP15 [348]. 
Our results show, however, that thioredoxin reductase inhibition is of limited 
importance for the cytotoxicity of b-AP15. Another important enzymatic system in 
regulating cellular redox-homeostasis is the glutathione system. We observed that 
glutathione reductase was not inhibited by b-AP15, suggesting selective binding of b-
AP15 to cellular cysteines (i.e. to thioredoxin reductase and proteasomal DUBs, but 
not to glutathione reductase). Somewhat surprisingly, b-AP15 was found to 
irreversible inhibit thioredoxin reductase, in distinction to the reversible inhibition of 
USP14. We do not understand the underlying difference with regard to inhibition, but 
believe it to be related to strong binding to the selenocysteine of thioredoxin 
reductase. 
 
    Almost one hundred cysteine DUBs have been identified in the human genome. 
Surprisingly, we have only been able to demonstrate inhibition of the activities of 
proteasomal DUB by b-AP15 [255, 322]. The Michael acceptors of the compound are 
expected to preferentially react with "hyper-reactive cysteines", demonstrated to 
encompass a minor fraction of all cellular cysteine [349, 350]. It is possible that 
USP14 and UCHL5 share some features which render them preferred targets for b-
AP15. Both USP14 and UCHL5 are activated by mechanism involving displacement 
of loops to expose the active site cleft to ubiquitin [247]. Alternatively, and perhaps 
more likely, also other DUBs are inhibited by b-AP15, but these interactions do not 
generate the same degree of cytotoxicity compared to the delirious consequences of 
inhibiting proteasomal DUBs. 
  
    In conclusion, even b-AP15 is a reversible inhibitor of deubiquitinating activity 
and proteasome function, it can be enriched in cells and rapidly committed to cell 
death within one hour of drug treatment. Importantly, cell death is intimately 
associated with proteasomal blocking as evidenced by induction of cell death only in 
cells which accumulate a proteasomal reporter.  
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3.6 Paper VI: Development of the proteasome deubiquitinase inhibitor VLX1570 
for treatment of multiple myeloma. 
        
      In this study, we describe and characterize the compound VLX1570, an optimized 
lead of the 19S deubiquitinase inhibitor b-AP15.  
 
      Similar to b-AP15, VLX1570 inhibits the enzymatic activities of both USP14 and 
UCHL5, leading to accumulation of high molecular weight polyubiquitinated 
proteins. VLX1570 was slightly more cytotoxic than b-AP15 on colon cancer cells 
and myeloma cells. Using the substrate Ub-AMC to determine 19RP DUB activity, 
VLX1570 showed a lower IC50 compared to b-AP15 (13.0 + 2.7 µM compared to 
16.8 + 2.8 µM). VLX1570 induces a similar gene expression profile as b-AP15 in 
MCF-7 cells. This response is characterized by induction of chaperones, induction of 
ER stress and oxidative stress. Furthermore, we compared the cytotoxicity of 
VLX1570 to that of b-AP15 in 14 human tumor cell lines. A correlation coefficient of 
0.93 was observed between the recorded IC50 values, indicating that VLX1570 
induces a similar cellular response as b-AP15. 
 
     b-AP15/VLX1570 induce gene expression profiles which are very similar to those 
induced by 20S proteasome inhibitors, and cell death is closely linked to proteasome 
inhibition in cells (Paper V). We were nevertheless concerned that the reactivity of b-
AP15/VLX1570 will lead to a wide range of off-target activities. To begin to address 
this issue we examined the ability of VLX1570 to inhibit the activity of cellular 
kinases. We did not, however, find significant inhibition (Cdk4 being the only kinase 
significantly inhibited at 10 µM). This result implies that off-target activities may not 
be as extensive as may have been envisioned. 
 
     In paper IV, we found that b-AP15 has activity in multiple myeloma in vitro and 
in vivo. We here investigated the cytotoxicity of VLX1570 on three multiple 
myeloma cell lines, RPMI8226, KMS-11 and OPM2. We found that VLX1570, 
similar to b-AP15, was effective in inducing apoptosis/cell death of myeloma cells. 
Apoptosis was confirmed by determining cleavage of caspase-3 and PARP in these 
cell lines. Similar to b-AP15 and the 20S proteasome inhibitor bortezomib, VLX1570 
induced p21Cip1, the chaperone Hsp70B' and the oxidative stress marker Hmox-1. 
VLX1570 also activated the JNK pathway in the multiple myeloma cell lines.   
 
     In paper IV, we also reported that b-AP15 can overcome resistance developed to 
the proteasome inhibitor bortezomib [255], providing a basis for future clinical use. 
In this study, we found that a multiple myeloma cell line (OPM2) selected for 
resistance to bortezomib, OPM2/BZ cells, showed a similar sensitivity to VLX1570 
as its parental derivative. Interestingly, OPM2/BZ cells were partially resistant to 
VLX1570-induced apoptosis. These findings are consistent with our previous notion 
that b-AP15 is able to overcome apoptosis resistance [322, 351]. The mechanism(s) 
underlying the strong induction of cell death by b-AP15 and VLX1570 are unclear at 
present, but may be due to induction of organelle damage by accumulated misfolded 
proteins. 
 
     We also studied the anti-multiple myeloma activity of VLX1570 in vivo. Growth 
inhibitory effects by VLX1570 were observed in two different human multiple 
myeloma xenograft-mouse models. These findings are consistent with our previous 
results showing anti-tumor activity of b-AP15 in multiple myeloma and solid tumor 
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xenograft models [322, 352]. Immunohistochemical analysis showed decreased ERK 
phosphorylation in tumors treated with VLX1570. In paper IV we were able to show 
increased levels of K48-linked polyubiquitin in tumors from b-AP15-treated animals. 
This result has been difficult to reproduce, probably due to different properties of 
antibodies. Further studies are required to determine which biomarker will be optimal 
in future pharmacodynamic studies. 
 
     We conclude that VLX1570 is a candidate agent for treatment of multiple 
myeloma. VLX1570 shows improved solubility compared to the hit molecule b-
AP15. The compound is currently undergoing toxicological studies in preparation for 
future clinical trials. 
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4. CONCLUSIONS 
Paper I 
! Clofarabine may inhibit DNA synthesis and can induce apoptosis in HCT116 
colon cancer cells. 
! Real-time analysis of drug uptake is useful for characterization of drug action in 
vitro. 
 
Paper II 
! The activities of different 5’-NTs are different in blood samples from patients.  
! The degradation of fludarabine monophosphate was associated with CN2 
activity, and the degradation of cladribine monophosphate was associated with 
CN1 activity.  
! The sensitivity of leukemic Molt4 cells to the purine analogues was attenuated 
by down-regulation of dCK.  
! The expression of anabolic and catabolic enzymes in tumor cells should be 
considered during treatment of CLL with nucleotide analogues. 
 
Paper III 
! VLX40 has identified as showing antiproliferative activity in a multidrug 
resistant model of myeloid leukemia. 
! VLX40 is a novel tubulin active agent that may be further developed for 
treatment of malignancies that are resistant to common chemotherapeutic 
agents. 
 
Paper IV 
! The proteasome DUB inhibitor b-AP15 shows anti-MM activity in vitro and in 
vivo. 
! This study provides proof of concept for evaluation of proteasome DUB 
inhibitors, alone and in combination, as potential therapy to improve patient 
outcome in MM. 
 
Paper V 
! The ability of b-AP15 to inhibit proteasome function and DUB activity is 
reversible. 
! b-AP15 is rapidly taken up and enriched in cells and elicits rapid commitment 
to apoptosis/cell death. 
! b-AP15 inhibits thioredoxin reductase. This activity is likely to contribute to 
oxidative stress but does not appear important for cell death. 
 
Paper VI 
! VLX1570 shows a similar cytotoxic profile and similar biochemical activity as 
b-AP15.  
! VLX1570 shows significant anti-MM activity in vitro and in vivo. 
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